Blade Therapeutics Initiates Additional Phase 1 Clinical Study of Cudetaxestat, a Non-Competitive Autotaxin Inhibitor in Clinical Development for Idiopathic Pulmonary Fibrosis Media ReleaseCarolyn MillerOctober 19, 2021Blade Therapeutics, Paul Kelly
Blade Therapeutics Announces FDA Orphan Drug Designation Granted to Cudetaxestat for Treatment of Systemic Sclerosis Media ReleaseCarolyn MillerOctober 14, 2021Blade Therapeutics, Paul Kelly
Blade Therapeutics Mourns the Passing of General Counsel and Secretary Alan C. Mendelson Media ReleaseCarolyn MillerOctober 11, 2021Blade Therapeutics
Blade Therapeutics Announces Publication of Preclinical Evidence Supporting Neuroprotective Effects of Proprietary Calpain Inhibitor in a Rare Inherited Neurodegenerative Disease Media ReleaseCarolyn MillerOctober 8, 2021Blade Therapeutics, Paul Kelly
OneVentures takes VC industry lead on ESG investment and oversight Media ReleaseCarolyn MillerAugust 31, 2021Michelle Deaker
Preclinical studies from Vaxxas and Collaborators Reveal Potential of Vaxxas’ Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine Media ReleaseCarolyn MillerJune 3, 2021Vaxxas, Paul Kelly
Clinical Genomics Announces Nationwide Expansion of Patient Access to COLVERA® Media ReleaseCarolyn MillerJanuary 12, 2021Clinical Genomics, Paul Kelly
OneVentures Growth (Equity) Fund V combines capital and executional support to tech companies Media ReleaseCarolyn MillerDecember 1, 2020Michelle Deaker, Grant Chamberlain
Clinical Genomics Announces Medicare Coverage Applicable to COLVERA® (Liquid Biopsy Test to Detect Recurrence of Colorectal Cancer) Media ReleaseCarolyn MillerNovember 16, 2020Clinical Genomics, Paul Kelly
Vaxxas Announces $22 Million Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response Media ReleaseCarolyn MillerOctober 6, 2020Paul Kelly, Vaxxas
Blade Therapeutics Updates Enrollment Progress for Phase 2 Study of Lead Investigational Therapy BLD-2660 in Treating Patients with COVID-19 Pneumonia Media ReleaseCarolyn MillerAugust 13, 2020Blade Therapeutics, Paul Kelly
Blade Therapeutics Appoints Accomplished Biopharmaceutical Executive, Mark Timney, as Chairman of the Board Media ReleaseCarolyn MillerAugust 10, 2020Blade Therapeutics, Paul Kelly
KiRA Biotech appoints Global Pharma Business Leader as Independent Board Chair Media ReleaseCarolyn MillerAugust 3, 2020Kira Biotech, Paul Kelly
FDA Approves Xeglyze™ for the topical treatment of head lice infestation Media ReleaseCarolyn MillerAugust 3, 2020Hatchtech, Paul Kelly
OneVentures Venture Credit Fund poised to invest $120M into Australian scaleups Media ReleaseCarolyn MillerJuly 22, 2020OneVentures
Vaxxas announces that MSD exercises option to apply novel immune system activation platform for vaccine candidate Media ReleaseCarolyn MillerMay 29, 2020Vaxxas, Paul Kelly
Harro Höfliger and Vaxxas announce alliance to develop industrial‐scale aseptic processing line for vaccine products based on Vaxxas’ High Density Microarray Patch (HD‐MAP) Media ReleaseCarolyn MillerMay 28, 2020Vaxxas, Paul Kelly
Clinical Genomics announces publication of Additional positive data reinforcing key benefits of COLVERA® Media ReleaseCarolyn MillerMay 27, 2020Clinical Genomics, Paul Kelly
OneVentures expands team to internationalise its healthcare portfolio Media ReleaseCarolyn MillerMay 19, 2020Paul Kelly
Clinical Genomics expands strategic relationship with Quest Diagnostics and further increases momentum for innovative first-line colorectal cancer screening blood test Media ReleaseCarolyn MillerApril 30, 2020Clinical Genomics, Paul Kelly
